222 related articles for article (PubMed ID: 19349520)
41. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.
Kiso M; Takahashi K; Sakai-Tagawa Y; Shinya K; Sakabe S; Le QM; Ozawa M; Furuta Y; Kawaoka Y
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):882-7. PubMed ID: 20080770
[TBL] [Abstract][Full Text] [Related]
42. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].
Fediakina IT; Shchelkanov MIu; Deriabin PG; Leneva IA; Gudova NV; Kondrat'eva TV; L'vov DK
Antibiot Khimioter; 2011; 56(3-4):3-9. PubMed ID: 21913403
[TBL] [Abstract][Full Text] [Related]
43. Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.
Lu Y; Jiang T
Protein Cell; 2013 May; 4(5):356-63. PubMed ID: 23589018
[TBL] [Abstract][Full Text] [Related]
44. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
Wang SQ; Du QS; Chou KC
Biochem Biophys Res Commun; 2007 Mar; 354(3):634-40. PubMed ID: 17266937
[TBL] [Abstract][Full Text] [Related]
45. Antiviral Susceptibilities of Avian Influenza A(H5), A(H7), and A(H9) Viruses Isolated in Japan.
Takashita E; Morita H; Nagata S; Shirakura M; Fujisaki S; Miura H; Takayama I; Arita T; Suzuki Y; Yamaoka M; Tanikawa T; Tsunekuni R; Mine J; Sakuma S; Uchida Y; Shibata A; Iwanaka M; Kishida N; Nakamura K; Kageyama T; Watanabe S; Hasegawa H;
Jpn J Infect Dis; 2022 Jul; 75(4):398-402. PubMed ID: 34980710
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
47. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Hurt AC; Lowther S; Middleton D; Barr IG
Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
[TBL] [Abstract][Full Text] [Related]
48. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt.
Earhart KC; Elsayed NM; Saad MD; Gubareva LV; Nayel A; Deyde VM; Abdelsattar A; Abdelghani AS; Boynton BR; Mansour MM; Essmat HM; Klimov A; Shuck-Lee D; Monteville MR; Tjaden JA
J Infect Public Health; 2009; 2(2):74-80. PubMed ID: 20701864
[TBL] [Abstract][Full Text] [Related]
49.
Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
[TBL] [Abstract][Full Text] [Related]
50. Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir.
Stoner TD; Krauss S; Turner JC; Seiler P; Negovetich NJ; Stallknecht DE; Frase S; Govorkova EA; Webster RG
Antiviral Res; 2012 Mar; 93(3):322-9. PubMed ID: 22252168
[TBL] [Abstract][Full Text] [Related]
51. Interactions of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.
Govorkova EA; Ilyushina NA; Marathe BM; McClaren JL; Webster RG
Influenza Other Respir Viruses; 2011 May; 5(Suppl 1):90-3. PubMed ID: 21751467
[No Abstract] [Full Text] [Related]
52. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.
Boltz DA; Rehg JE; McClaren J; Webster RG; Govorkova EA
J Infect Dis; 2008 May; 197(9):1315-23. PubMed ID: 18422444
[TBL] [Abstract][Full Text] [Related]
53. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Choi WS; Jeong JH; Kwon JJ; Ahn SJ; Lloren KKS; Kwon HI; Chae HB; Hwang J; Kim MH; Kim CJ; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046464
[TBL] [Abstract][Full Text] [Related]
54. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.
Kumaki Y; Day CW; Smee DF; Morrey JD; Barnard DL
Antiviral Res; 2011 Nov; 92(2):329-40. PubMed ID: 21925541
[TBL] [Abstract][Full Text] [Related]
55. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368
[TBL] [Abstract][Full Text] [Related]
56. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.
Smee DF; Hurst BL; Wong MH; Bailey KW; Tarbet EB; Morrey JD; Furuta Y
Antimicrob Agents Chemother; 2010 Jan; 54(1):126-33. PubMed ID: 19901093
[TBL] [Abstract][Full Text] [Related]
57. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
Abed Y; Nehmé B; Baz M; Boivin G
Antiviral Res; 2008 Feb; 77(2):163-6. PubMed ID: 17919743
[TBL] [Abstract][Full Text] [Related]
58. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
Smee DF; Hurst BL; Wong MH; Bailey KW; Morrey JD
Antimicrob Agents Chemother; 2009 May; 53(5):2120-8. PubMed ID: 19273672
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
60. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Ikematsu H; Kawai N
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
